EUCTR2007-006188-59-SE进行中（未招募）不适用
A multicenter, randomised double blind, placebo-controlled study of efficacy, safety and tolerability of Kaprolac® K301 for the treatment of seborrhoeic eczema (SE) of the scalp.
Moberg Derma AB0 个研究点开始时间: 2007年11月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female (including fertile women)
- •18-70 years of age
- •SE of the scalp for at least 2 months
- •Presenting erythema and desquamation of mild to moderate intensity
- •Signed written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •SE or any other cutaneous disease of the face or scalp requiring a specific topical treatment (corticosteroids, antifungals, selenium sulphide, antibiotics, retinoids, benzoyl peroxide or a-hydroxyacids) during the previous 15 days
- •Oral treatment with cyclines, lithium, antifungals or inhaled corticosteroids during the previous month
- •Use of systemic corticosteroids and retinoids during the previous 2 months
- •SE associated with Parkinson’s disease, human immunodeficiency virus (HIV) infection
- •Current or any history of ear, nose, and throat carcinoma
- •Current or any history of severe concomitant disease according to investigator’s judgement
- •Allergy to any of the tested treatment components
- •Subject who has been previously enrolled in the phase II study K40-3 investigating Kaprolac® K40
研究者
相似试验
招募中
不适用
A double-blind randomised multi-centre, placebo-controlled trial of combined angiotensin converting enzyme-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with Duchenne Muscular Dystrophy without echo-detectable left ventricular dysfunctioNervous System DiseasesDiseases of myoneural junction and muscleDuchenne muscular dystrophyISRCTN50395346ewcastle upon Tyne Hospitals NHS Foundation Trust (UK)140
进行中（未招募）
1 期
A double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction - DMD-Heart ProtectioMedDRA version: 9.1 Level: LLT Classification code 10013801 Term: Duchenne muscular dystrophyDuchenne muscular dystrophyEUCTR2007-005932-10-GBewcastle upon Tyne Hospitals NHS Foundation Trust85
已完成
2 期
A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy - the RESMAIN Studycutaneous lymphomaMycosis fungoides / Sézary Syndrome10025321NL-OMON557444SC AG3
进行中（未招募）
1 期
The purpose of this research study is to determine if the new drug resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary Syndrome that have achieved disease control with previous systemic therapy, recentlyMedDRA version: 20.0Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeSystem Organ Class: 100000004864Advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapyEUCTR2016-000807-99-GB4SC AG150
进行中（未招募）
1 期
The purpose of this research study is to determine if the new drug resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary Syndrome that have achieved disease control with previous systemic therapy, recentlyAdvanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapyMedDRA version: 19.0Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeSystem Organ Class: 100000004864EUCTR2016-000807-99-ES4SC AG150